A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004

Status	RECRUITING
Phase	Phase 3
Sponsor	argenx
Enrollment	218 participants

Key Eligibility Criteria

Inclusion (5)

- Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
- Has responded to IVIg in the past 5 years
- Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg
- Has residual disability and active disease

Exclusion (3)

- Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
- Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- Use of other long-acting immunomodulatory treatment

Locations (46 total)

Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
Homestead Associates in Research Inc, Homestead, Florida, United States
... and 43 more locations